Your session is about to expire
← Back to Search
Blood Clot Treatments for Stroke (MOST Trial)
MOST Trial Summary
This trial is comparing two different blood clot treatments to see which one results in better outcomes for patients who have had a stroke.
MOST Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMOST Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MOST Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I received clot-busting medication within 3 hours after my stroke started.Women who could become pregnant have a positive pregnancy test in their urine or blood.I have taken blood thinners like Fondaparinux, apixaban, or rivaroxaban in the last 2 days.I can take the study medication within 60 to 75 minutes after starting IV thrombolysis.You have a score of 6 or higher on the NIH Stroke Scale before receiving IV thrombolytic treatment.I have had a stroke within the last 3 months.I have a bleeding disorder or take blood thinners with an INR over 1.5.My CT scan shows a large area of damage in my brain's middle region.I have not had any surgery or biopsy on an organ in the last 30 days.I have not had a serious bleeding issue in the last 30 days.I am currently on kidney dialysis.I have taken medication for blood clots within the last 2 weeks.I have had a brain bleed, tumor, or abnormal blood vessel formation.I was suspected to have a brain bleed despite a normal initial CT scan.My blood pressure remains high (>180mmHg) after treatment for a clot.Your hematocrit level is less than 25%.I am not currently in a drug or device trial, or it has been over 90 days since I last participated.My blood clotting test was abnormal after taking certain blood thinners.You had a serious head injury in the last 90 days.My blood pressure remains high after treatment.Your blood sugar level is lower than 50 or higher than 400 mg/dl.I have had a recent stroke caused by a blood clot.You have a dense area in your body that shows signs of bleeding.Your platelet count is less than 100,000 per cubic millimeter.Your blood clotting test (PTT) shows higher levels than normal.I do not have any serious illnesses that would make specific treatments risky for me.I do not have a severe neurological or psychiatric condition that affects my daily activities.I have had internal injuries or open sores from an injury in the last month.I have taken a full dose of a blood thinner like Dalteparin, Enoxaparin, or Tinzaparin in the last 24 hours.I am 18 years old or older.Your creatinine level is higher than 4 mg/dl.You are allergic to argatroban or eptifibatide.
- Group 1: Argatroban
- Group 2: Eptifibatide
- Group 3: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are we still enrolling patients for this test?
"Yes, this trial is still open to patients according to the listing on clinicaltrials.gov. The posting went up on 2019-10-15 and was edited as recently as 2022-06-06."
What other similar trials have preceded this one?
"There are 5 ongoing clinical trials for Argatroban in 94 cities and 12 countries. The first clinical trial was completed in 2019 by Aspen Global Incorporated. That study reached Phase 3 approval after 508 patients were enrolled. In the two years since, 18264 trials have been completed."
What other investigations have been conducted with Argatroban?
"Argatroban was first studied in 2019 at the Regional Hospital after N.N Burdenko. So far, there have been 18264 completed clinical trials. There are 5 trials currently recruiting, with a large concentration of these studies based in Los Angeles, California."
Are there any mortal risks associated with Argatroban?
"Argatroban's safety is well-documented, as this is a Phase 3 trial."
Is this a widespread trial or limited to a few hospitals?
"This study is enrolling patients at multiple sites across the United States, including the Kaiser Permanente Los Angeles Medical Center in Los Angeles, California, the Baptist Medical Center Jacksonville in Jacksonville, Florida, and the Jackson Memorial Hospital in Miami, Ohio."
What are the main medical conditions that Argatroban is used to manage?
"Argatroban is indicated for the treatment of acute chest syndrome, thrombosis prophylaxis, and percutaneous coronary intervention (pci)."
How many people can join this experiment at most?
"That is correct. The online clinical trial registry lists this study as open and currently recruiting patients. This trial was first posted on 2019-10-15 and was most recently edited on 2022-06-06. They are looking for a total of 1200 participants across 76 sites."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger